Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04339426 · ClinicalTrials.gov registry record · Phase 2
Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection
A Phase 2 study, sponsored by HonorHealth Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04339426 is a Phase 2 study that was terminated before completion, run by HonorHealth Research Institute. The registered enrollment target is 3 participants.
The verdict
NCT04339426, a Phase 2 study, was terminated before completion, sponsored by HonorHealth Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study will evaluate anti-malarial/anti-infective single-agent and in combination for patients with confirmed COVID-19 infection. The first combination to be evaluated is atovaquone and azithromycin.
Interventions
- DRUG Atovaquone/Azithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-04-20 |
| Est. Completion | 2022-02-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04339426
The ClinicalTrials.gov registry entry for NCT04339426 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HonorHealth Research Institute, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atovaquone/Azithromycin is the first listed.
NCT04339426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04339426 about?
NCT04339426 is a clinical study titled "Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection". This study will evaluate anti-malarial/anti-infective single-agent and in combination for patients with confirmed COVID-19 infection. The first combination to be evaluated is atovaquone and azithromycin.
What is the current status of trial NCT04339426?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2020-04-20. Estimated completion is 2022-02-11.
What interventions are being tested in trial NCT04339426?
The interventions under investigation include: Atovaquone/Azithromycin (DRUG).
Who is sponsoring clinical trial NCT04339426?
This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.